Heat shock protein 90 inhibitors in non-small-cell lung cancer

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Current Opinion in Oncology

• Publication date

  2014-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/CCO.0000000000000047PMID 24463348
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation.

  2014cited by this paper
• First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors

  2013cited by this paper
• A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer

  2013cited by this paper
• Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non–Small-Cell Lung Cancer

  2013cited by this paper
• Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

  2013cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• Inhibition of HSP90 molecular chaperones: moving into the clinic.

  2013cited by this paper
• Reply to M.C. Garassino et al.

  2013cited by this paper
• A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).

  2013cited by this paper
• GALAXY-1: Randomized phase II study of docetaxel with or without ganetespib in advanced lung adenocarcinoma: Results in biomarker sub-groups and all adenocarcinoma patients.

  2013cited by this paper
• A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs).

  2013cited by this paper
• The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non‐small cell lung cancer

  2012cited by this paper
• Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models

  2012cited by this paper
• Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib

  2012cited by this paper
• Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer

  2012cited by this paper
• A phase I and pharmacokinetic study of multiple schedules of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel for subjects with advanced solid tumor malignancies.

  2012cited by this paper
• The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models

  2011cited by this paper
• Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

  2011cited by this paper
• Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC).

  2011cited by this paper
• Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

  2010cited by this paper
• Targeting HSP90 for cancer therapy

  2009cited by this paper
• Cancer statistics

  1989cited by this paper

• The role of heat shock protein 90 in idiopathic pulmonary fibrosis: state of the art

  2025cites this paper
• ALK F1174S mutation impairs ALK kinase activity in EML4-ALK variant 1 and sensitizes EML4-ALK variant 3 to crizotinib

  2024cites this paper
• The active components of Smilax china L. against cancer by interfering with the interactions among associated proteins

  2023cites this paper
• Targeted Inhibition of Hsp90 in Combination with Metformin Modulates Programmed Cell Death Pathways in A549 Lung Cancer Cells

  2023cites this paper
• An Updated Review on KRAS Mutation in Lung Cancer (NSCLC) and Its Effects on Human Health

  2023influential citation
• Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy

  2023cites this paper
• Therapeutic Targeting Hypoxia-Inducible Factor (HIF-1) in Cancer: Cutting Gordian Knot of Cancer Cell Metabolism

  2022cites this paper
• Regulation of ClC-2 Chloride Channel Proteostasis by Molecular Chaperones: Correction of Leukodystrophy-Associated Defect

  2021cites this paper
• Discovery of an orally active antitumor agent that induces apoptosis and suppresses EMT through heat shock protein 90 inhibition

  2021cites this paper
• Hsp90 inhibitor gedunin causes apoptosis in A549 lung cancer cells by disrupting Hsp90:Beclin-1:Bcl-2 interaction and downregulating autophagy.

  2020cites this paper
• Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.

  2020cites this paper
• Defective Gating and Proteostasis of Human ClC-1 Chloride Channel: Molecular Pathophysiology of Myotonia Congenita

  2020cites this paper
• Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells.

  2020cites this paper
• Senescence and Cancer: Role of Nitric Oxide (NO) in SASP

  2020cites this paper
• Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion–positive non–small cell lung cancer cells

  2020cites this paper
• Title Targeting hypoxic response for cancer therapy

  2019cites this paper
• Discovery of novel HSP90 inhibitors that induced apoptosis and impaired autophagic flux in A549 lung cancer cells.

  2018cites this paper
• Molecular mechanism and targeted therapy of Hsp90 involved in lung cancer: New discoveries and developments (Review).

  2017cites this paper
• Hsp90 regulation of fibroblast activation in pulmonary fibrosis.

  2017cites this paper
• ALK alterations and inhibition in lung cancer.

  2017cites this paper
• The Association Between HSP90/topoisomerase I Immunophenotype and the Clinical Features of Colorectal Cancers in Respect to KRAS Gene Status.

  2017cites this paper
• The Translational Applications of Using Oxadiazole-Derived Small-Molecule Agents to Induce Protein Degradation Pathways

  2017cites this paper
• ALK mutation and inhibition in lung cancer

  2017cites this paper
• DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF MORPHOLINE, PIPERIDINE AND PHENYL DERIVATIVES OF QUINAZOLINONE AS HSP90 ATPASE INHIBITORS

  2017cites this paper
• Targeting hypoxic response for cancer therapy

  2016cites this paper
• Emerging roles of NudC family: from molecular regulation to clinical implications

  2016cites this paper
• Translational Medicine Case Studies and Reports

  2016cites this paper
• Regulation of CLC-1 chloride channel biosynthesis by FKBP8 and Hsp90β

  2016cites this paper
• Molecular markers in Finnish lung cancers

  2016cites this paper
• Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy

  2015cites this paper
• Resistance to HSP90 inhibition involving loss of MCL1 addiction

  2015cites this paper
• Combined inhibition of heat shock proteins 90 and 70 leads to simultaneous degradation of the oncogenic signaling proteins involved in muscle invasive bladder cancer

  2015cites this paper
• S-Nitrosylation in Cancer Cells: To Prevent or to Cause?

  2015cites this paper
• Pharmacogenomics in the treatment of lung cancer: an update.

  2015cites this paper
• Anaplastic lymphoma kinase: Role in cancer and therapy perspective

  2015cites this paper
• Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer

  2015cites this paper
• Substrate recognition and function of the R2TP complex in response to cellular stress

  2015cites this paper
• Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors.

  2014cites this paper
• Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer

  2014cites this paper
• A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer

  2014cites this paper
• Cancer-Selective Induction of Apoptosis by Leczyme

  2014cites this paper
• ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.

  2014cites this paper